Upgrade to SI Premium - Free Trial

BofA on PTC Therapeutics (PTCT): 'See opportunity for >$2bn in global Sephience sales'

May 20, 2026 10:46 AM
BofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $93.00 price target on PTC Therapeutics (NASDAQ: PTCT).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments